1. Miller J. Ogidigben, Teh-Ching Chu and David E. Potter. Naphazoline-induced neuroendocrine changes Increases in ANP and cGMP levels 2. Robert J. Dockhorn and Thomas G. Duckett. Comparison of Naphcon-A and Its components 3. Mark B, Abelson MD, Salim I, et al. Tolerance and absence of rebound vasodilation following topical ocular decongestant usage 4. Ogidigben MJ, Chu TC, Potter DE. Naphazoline-induced suppression of aqueous humor pressure and flowinvolvement of central and peripheral alpha(2) I(1) receptors 5. The efficacy of long-term treatment with Tolvaptan to prolong the time until dialysis initiation in patients with chronic kidney disease and heart failure 6. Renoprotective effects of tolvaptan in hypertensive heart failure rats depend on renal decongestion 7. Tolvaptan Efficiently Reduces Intracellular Fluid Working Toward a Potential Treatment Option for Cellular Edema 8. Analysis of tolvaptan non-responders and outcomes of tolvaptan treatment of ascites 9. Tolvaptan in Japanese patients with later-stage autosomal dominant polycystic kidney disease 10. Safety and Effectiveness of Tolvaptan Administration after Total Arch Replacement 11. Nephrol Dial Transplant. 2018 Oct 12. doi 10.1093ndtgfy297. [Epub ahead of print] 12. Nephrol Dial Transplant. 2018 Oct 11. doi 10.1093ndtgfy298. [Epub ahead of print] 13. Development and validation of RP-HPLC method for simultaneous estimation of Ofloxacin and Ornidazole inpresence of Ornidazole Impurity in combined pharmaceutical dosage form 14. Stability-indicating methods for the determination of Ornidazole in the presence of its degradate according to ICH guidelines 15. A sensitive HPLC method of determination of 2-methyl 5-nitro imidazole & reaction mass of intermediates of ornidazole in ornidazole bulk manufacturing 16. Development and validation of a reversed-phase HPLC method for the analysis of ornidazole in pharmaceutical dosage forms 17. On the hydrolytic behavior of tinidazole, metronidazole,   [更多]

標(biāo)題： 1、Morisset M et al. Allergy to cow milk proteins contaminating lactose, common excipient of dry powder inhalers for asthma. J Allergy Clin Immunol 2006; 117(Suppl. 1): 95 2、Safety and tolerability of selumetinib as a monotherapy, or in combination with docetaxel as second-line therapy, in Japanese patients with advanced solid malignancies or non-small cell lung cancer. 3、Preparation and characterization of a cocrystalline suspension of [LysB28,ProB29]-human insulin analogue. DeFelippis MR1, Bakaysa DL, Bell MA, Heady MA, Li S, Pye S, Youngman KM, Radziuk J, Frank BH 1、Heterocycles, 2001 , vol. 55, # 2 p. 331 - 352 4、R. G. Strickley, L. Liu, and P. Lapresca. Preclinical parenteral and oral formulations of water insoluble molecules. ISSX Meet- ing, Nashville, TN (USA) Abstract # 291 (1999). (Z) 5、465: A possible genetic signature of DNA repair genes in triple negative breast cancers by a NGS approach 4、Systemic exposure to?atorvastatin?between Asian and Caucasian subjects: a combined analysis of 22 studies. 6、 Evaluation of cardiovascular morbidity associated with adherence to?atorvastatin?therapy. 7、Beta-lactam antibiotics: their role in the management of infections in children 8、China type 2 diabetes treatment status survey of treatment pattern of oral drugs users. J Diabetes. 2015 Mar;7(2):166-73 9、Non‐steroidal anti‐inflammatory drugs and upper gastrointestinal bleeding, a post‐marketing surveillance case‐control study 10、Individual nonsteroidal antiinflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation. 備注：將符合要求文獻(xiàn)的PDF格式打包上傳   [更多]

標(biāo)題： 1、PMID：29241352 Rhabdomyolysis and elevated liver enzymes after rapid correction of hyponatremia due to pneumonia and concurrent use of aripiprazole: a case report 2、PMID：18306096 Hyponatremia in psychiatric patients: update on evaluation and management 3、PMID：20643634 The assessment and treatment of water imbalance in patients with psychosis 4、Marí M, Morales A, Colell A, García-Ruiz C, Fernández-Checa JC. Mitochondrial glutathione, a key survival anti-oxidant. Antioxid Redox Signal. (2009) 11(11)2685-700 5、Yeni D;Effect of α-lipoic acid on sperm quality, reproductive tract measures in thinner exposed rats. 6、PRELIMINARY BASELINE DATA OF HYPERTENSIVE PATIENTS INCLUDED IN THE CATCH (CANDESARTAN ASSESSMENT IN THE TREATMENT OF CARDIAC HYPERTROPHY) STUDY: P1.195 7、Synthesis and antibacterial activity of 1-cyclopropyl-6,8-difluoro-7-(2-substituted 4,6-dihydro-1H-pyrrolo[3,4-d]thiazol-5-yl)-1,4-dihydro-4-oxoquinoline-3-carb oxylic acid 8、Steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected Chinese patients: Expert Review of Clinical Pharmacology: Vol 10, No 7 9、Bioequivalence study of two oral tablet formulations containing tenofovir disoproxil fumarate in healthy volunteers. - PubMed - NCBI 10、 Huiming Ma.Protective function of alpha-lipoic acid on sperm motility and mitochondrial function during goat sperm-mediated gene transfer[J].Small Ruminant Research 99 (2011) 191-198 11、The safety of medical devices containing DEHP plasticized PVC or other plasticizers on neonates and other groups possibly at risk (2015 update). 12、Mechanisms of recognition of amyloid-β (Aβ) monomer, oligomer, and fibril by homologous antibodies. 將符合標(biāo)題的文獻(xiàn)PDF格式上傳，按照交稿時(shí)間的先后確認(rèn)稿件，先到先得   [更多]

醫(yī)療機(jī)構(gòu)制劑質(zhì)量體系文件全套模板，包括目錄和具體文件內(nèi)容，中藥制劑。   [更多]

詳細(xì)要求： 需求名稱(chēng)：黃體酮陰道緩釋凝膠東南亞質(zhì)量標(biāo)準(zhǔn) 具體要求：泰國(guó)、馬來(lái)西亞等東南亞國(guó)家均可。 要求時(shí)間：請(qǐng)?jiān)?022年1月之前 價(jià)格可以添加QQ后商議   [更多]

信息范圍： 信息對(duì)象-職務(wù)：采購(gòu)部門(mén)的采購(gòu)經(jīng)理或采購(gòu)負(fù)責(zé)人 信息對(duì)象所在單位：XXX藥物研究院，XXX藥業(yè)、XXX制藥- 集團(tuán)有限公司、股份有限公司等 信息內(nèi)容：EXCEL列表最佳，按條算，信息真實(shí)能聯(lián)系到人即可 稱(chēng)謂：XXX先生/女士/職務(wù) 公司名稱(chēng)：XXXXX有限公司 聯(lián)系方式：QQ號(hào)，手機(jī)號(hào)碼，辦公室座機(jī)號(hào)碼 信息越完整越好，不得重復(fù)   [更多]

具體要求請(qǐng)聯(lián)系我個(gè)人QQ 2301984467   [更多]

1. 年凈利潤(rùn)2000-3000萬(wàn)。 2. 有核心產(chǎn)品。 3. 有被收購(gòu)意向。 提供信息請(qǐng)包括：企業(yè)名稱(chēng)、聯(lián)系人、聯(lián)系方式 信息經(jīng)核對(duì)真實(shí)，方可獲得賞金，謝謝藥智的戰(zhàn)友們。   [更多]

1懸賞的藥品注冊(cè)信息為2013年1月1日之后NMPA不批準(zhǔn)、退審的藥品注冊(cè)信息,以及補(bǔ)充藥品注冊(cè)信息 2必須提供完整注冊(cè)信息,以附件形式提交 3核實(shí)后如果正確,每個(gè)藥品注冊(cè)信息獎(jiǎng)勵(lì)100元 4投稿時(shí)請(qǐng)隱藏提交 5請(qǐng)勿在百度上直接搜索 6需是未收集的數(shù)據(jù)   [更多]

不需要江西省醫(yī)療機(jī)構(gòu)制劑規(guī)程__2020年版、湖北省醫(yī)療機(jī)構(gòu)制劑規(guī)范 2011年版、北京醫(yī)療機(jī)構(gòu)制劑標(biāo)準(zhǔn)2014一版、廣東省醫(yī)療機(jī)構(gòu)制劑規(guī)范(第六冊(cè))、山東省醫(yī)療機(jī)構(gòu)制劑規(guī)范 第1冊(cè) 第1版_2012、天津市醫(yī)療機(jī)構(gòu)制劑規(guī)范2016增補(bǔ)本。   [更多]